Health and Healthcare
Medivation, A Pain in the Rear for Dendreon (MDVN, DNDN)
Published:
Medivation, Inc. (NASDAQ: MDVN) is today’s darling in biotech and emerging pharmaceuticals. It and partner Astellas in Japan showed very positive data on its prostate cancer drug candidate.
Its shares are up more than 100% after clinical data on its prostate cancer drug candidate showed to be so effective. Medivation has even halted the clinical trial so that it can give the medicine to all participants.
The MDV3100 tial was in the final development stage for potential U.S. FDA marketing approval. The interim data indicated that patients lived an average of 4.8 months longer than those on a placebo.
That is going to only be added pressure for Dendreon Corporation (NASDAQ: DNDN). Its stock was down on its own earnings and disappointing Provenge sales figures. With the potential added competition on top of bad results, Dendreon’s stock is off by 35% to $6.77 and shares put in a new 52-week low of $6.56 this morning.
Medivation is up 113% at $35.10 and we are already more than ten-times normal trading volume.
JON C. OGG
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
